Sotrovimab restores neutralization against current Omicron subvariants in patients with blood cancer.
Date
2023-05-08Author
Wu, MY
Shepherd, STC
Fendler, A
Carr, EJ
Au, L
Harvey, R
Dowgier, G
Hobbs, A
Herman, LS
Ragno, M
Adams, L
Schmitt, AM
Tippu, Z
Shum, B
Farag, S
Rogiers, A
O'Reilly, N
Bawumia, P
Smith, C
Carlyle, E
Edmonds, K
Del Rosario, L
Lingard, K
Mangwende, M
Holt, L
Ahmod, H
Korteweg, J
Foley, T
Barber, T
Hepworth, S
Emslie-Henry, A
Caulfield-Lynch, N
Byrne, F
Deng, D
Williams, B
Brown, M
Caidan, S
Gavrielides, M
MacRae, JI
Kelly, G
Peat, K
Kelly, D
Murra, A
Kelly, K
O'Flaherty, M
Popat, S
Yousaf, N
Jhanji, S
Tatham, K
Cunningham, D
Van As, N
Young, K
Furness, AJS
Pickering, L
Beale, R
Swanton, C
Gandhi, S
Gamblin, S
Bauer, DLV
Kassiotis, G
Howell, M
Walker, S
Nicholson, E
Larkin, J
Wall, EC
Turajlic, S
CAPTURE consortium,
Type
Journal Article
Metadata
Show full item recordAbstract
Wu et al. report that patients with hematologic malignancies have reduced immunity against SARS-CoV-2 Omicron subvariants and Sotrovimab retains neutralizing capacity against all tested Omicron subvariants.
Collections
Subject
Humans
COVID-19
SARS-CoV-2
Hematologic Neoplasms
Neoplasms
Research team
Melanoma & Kidney Cancer
Medicine (RMH)
Language
eng
Date accepted
2023-04-06
License start date
2023-05-08
Citation
Cancer Cell, 2023, 41 (5), pp. 821 - 823
Publisher
CELL PRESS